摘要
目的 探讨盐酸埃克替尼治疗晚期非小细胞肺癌的应用效果.方法 选择52例晚期非小细胞肺癌患者作为研究对象,采取计算机随机分为常规组和研究组,每组26例.对常规组患者采取多西他赛进行治疗,对研究组患者采取盐酸埃克替尼进行治疗,对比两组的治疗效果.结果 研究组疾病控制率为84.62％,明显高于常规组的57.69％,差异有统计学意义（x^2=4.591,P=0.032）;研究组无进展生存期为（5.54±0.23）个月,长于常规组的（4.52±0.22）个月,差异有统计学意义（t=16.341,P=0.000）;研究组不良反应发生率为23.08％,明显低于常规组的50.00％,差异有统计学意义（x^2=4.063,P=0.044）.结论 对晚期非小细胞肺癌患者采取盐酸埃克替尼进行治疗的疗效显著,药物安全性相对较高,能够帮助患者延长生存期,值得实践推广.
Objective To explore the effect of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer （NSCLC）.Methods 52 patients with advanced NSCLC were selected as the research subjects,and they were divided into conventional group and study group by the computer random grouping method,26 cases in each group.The conventional group took docetaxel treatment,and the study group took icotinib hydrochloride treatment.The treatment effect of the two groups was compared.Results The disease control rate of the study group was 84.62%,which was significantly higher than 57.69% of the conventional group,the difference was statistically significant（x2 =4.591,P =0.032）.The progression free survival of the study group was （5.54 ±0.23）months,which was longer than （4.52 ± 0.22） months of the conventional group,the difference was statistically significant （t =16.341,P =0.000）.The incidence rate of adverse reaction of the study group was 23.08%,which was significantly lower than 50.00% of the conventional group,the difference was statistically significant（x2 =4.063,P =0.044）.Conclusion The effect of icotinib hydrochloride in the treatment of advanced NSCLC is distinct,and drug safety is relatively high,it can help prolong survival of patients,and it is worthy of popularizing practice.
出处
《中国基层医药》
CAS
2017年第23期3621-3624,共4页
Chinese Journal of Primary Medicine and Pharmacy
关键词
癌
非小细胞肺
盐酸埃克替尼
治疗结果
Carcinoma,Non-Small-Cell Lung
Icotinib Hydrochloride
Treatment Outcome
